Monopar Therapeutics (MNPR) Retained Earnings (2016 - 2026)
Monopar Therapeutics (MNPR) posted Retained Earnings of -$89.5 million for Q4 2025, down 6.16% sequentially from -$84.3 million in Q3 2025, and down 248766.37% YoY from N/an in Q4 2024.
Monopar Therapeutics (MNPR) Retained Earnings (2016 - 2026) Analysis & Trends
Monopar Therapeutics has reported Retained Earnings for 10 years, with the latest figure at -$89.5 million in Q4 2025.
- Quarterly Retained Earnings fell 248766.37% year-over-year to -$89.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$89.5 million (down 248766.37% YoY) and the FY2025 annual result came in at -$89.5 million, down 248766.37% from the prior year.
- Retained Earnings declined to -$89.5 million in Q4 2025 per MNPR's latest filing, from -$84.3 million in the prior quarter.
- Over five years, Retained Earnings peaked at $60.7 million in Q1 2022 and troughed at -$89.5 million in Q4 2025.
- A 5-year average of -$28.0 million and a median of -$18.1 million in 2021 frame the typical range for Retained Earnings.
- The widest YoY moves for Retained Earnings: up 1190591.06% in 2022, down 1639267.75% in 2022.
- Over 5 years, Retained Earnings stood at -$3160.0 in 2021, then tumbled by 1639267.75% to -$51.8 million in 2022, then jumped by 99.97% to -$14132.0 in 2023, then soared by 354.68% to $35992.0 in 2024, then slumped by 248766.37% to -$89.5 million in 2025.
- According to Business Quant data, Retained Earnings over the past three periods registered -$89.5 million, -$84.3 million, and $77577.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Monopar Therapeutics | 965.64 Mn | 912.88 Mn | - | -98.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -98.72 Mn |
| Dec 31, 2025 | -89.50 Mn |
| Sep 30, 2025 | -84.31 Mn |
| Jun 30, 2025 | 77,577.00 |
| Mar 31, 2025 | -78.42 Mn |
| Dec 31, 2024 | 35,992.00 |
| Sep 30, 2024 | -10,991.00 |
| Jun 30, 2024 | 8,258.00 |
| Mar 31, 2024 | -61.80 Mn |
| Dec 31, 2023 | -14,132.00 |
| Sep 30, 2023 | -58.40 Mn |
| Jun 30, 2023 | -56.40 Mn |
| Mar 31, 2023 | -54.24 Mn |
| Dec 31, 2022 | -51.80 Mn |
| Sep 30, 2022 | -48.91 Mn |
| Jun 30, 2022 | 17,466.00 |
| Mar 31, 2022 | 60.70 Mn |
| Dec 31, 2021 | -3,160.00 |
| Sep 30, 2021 | -5,147.00 |
| Jun 30, 2021 | -36.15 Mn |